SCHEMBL5325110

SCHEMBL5325110

CCC(CCC(N)C(=O)O)CC(N)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.50
PMP22 Q01453 2/20 0.50
ALOX15 P16050 1/20 0.50
BLM P54132 1/20 0.50
GCLC P48506 2/20 0.46
SLC1A3 P43003 3/20 0.42
SLC1A2 P43004 3/20 0.42
SLC1A1 P43005 3/20 0.42
NOS1 P29475 7/20 0.42
DDAH1 O94760 2/20 0.42
GRIK1 P39086 2/20 0.42
GRIK2 Q13002 2/20 0.42
CYP1A2 P05177 2/20 0.42
GSR P00390 2/20 0.42
GRM8 O00222 1/20 0.42
GRM6 O15303 1/20 0.42
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
GRM5 P41594 1/20 0.42
GRIA1 P42261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5319573 0.87 KMT2A (0.48) KMT2APMP22ALOX15BLMGCLC
SCHEMBL25342795 0.86 GCLC (0.53) KMT2APMP22ALOX15BLMGCLC
Hydrochloric Acid SCHEMBL28550970 0.84 GCLC (0.52) KMT2APMP22ALOX15BLMGCLC
SCHEMBL5325249 0.82 SLC1A2 (0.53) KMT2APMP22ALOX15BLMSLC1A3
SCHEMBL28935537 0.80 GCLC (0.49) KMT2APMP22ALOX15BLMGCLC
SCHEMBL28935535 0.80 GCLC (0.49) KMT2APMP22ALOX15BLMGCLC
SCHEMBL7136251 0.78 SLC1A3 (0.34) SLC1A3SLC1A2SLC1A1
SCHEMBL7895720 0.77 CA2 (0.40) SLC1A3SLC1A2SLC1A1GRIK1GRIK2
SCHEMBL276429 0.76
SCHEMBL5580195 0.76 BHMT (0.56) KMT2APMP22ALOX15BLMSLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070258899-A1 Diagnostic and therapeutic agents KARYON-CTT LTD (FI) 2007-11-08 US disclosed
WO-2007113385-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS KARYON-CTT LTD (FI) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070258899-A1 Diagnostic and therapeutic agents YBX1, MLX, TPX2 KMT2A 3586/4885PMP22 990/4885ALOX15 4182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.